arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Inhibrx Biosciences, Inc.

INBX

$88.72 ▲ +3.28 (+3.85%) at close

14 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Inhibrx Biosciences, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -20.1% ↗

FCF / Share $-2.44

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -8.32

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-33.44M

↑ +22.8% —

FCF / Share Free cash flow per share

$-2.44

↓ -5.1% —

Long-Term Debt Long-term obligations

$174.99M

↑ +74.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health →

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	—	N/M	—	1200.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+14900%)	—	-93.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1274%)	N/M	233.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2817%)	—	—	—	—	—	—
EPS Growth YoY (%)	23.2% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	58.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	19.7% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	51.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	31.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	35.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	—	—	—	—
Net Income Growth YoY (%)	22.8% Good ↓ Good Declining Year-over-year change in net income	31.4% Excellent ↓ Excellent Declining Year-over-year change in net income	45.0% Excellent → Excellent Stable Year-over-year change in net income	45.0% Excellent ↑ Excellent Improving Year-over-year change in net income	45.0% Excellent ↑ Excellent Improving Year-over-year change in net income	48.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-60.9% Weak Weak Year-over-year change in net income	-60.9% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-5.1% Weak Weak Year-over-year change in free cash flow	—	—	—	50.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	1.14x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-20.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-28.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-16.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-37.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-26.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-73.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-638.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	166.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-16.8% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-21.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-12.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-21.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-62.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-28.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	159.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+960%)	—	-117.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-884%)	-63.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-521%)	-45.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-406%)	-35.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-339%)	-44.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-394%)	-35.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-339%)	—	-215.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1534%)	-37.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-352%)	197.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1214%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	-8.32x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-1487%)	12.58x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+1997%)	2.71x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+352%)	1.45x Caution ↑ Caution Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+141%)	1.04x Caution ↑ Caution Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+74%)	0.00x Excellent → Excellent Stable Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	4.76x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+693%)	—	—	—	—
Interest Coverage (x)	-11.13x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-12.30x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-13.29x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-10.77x Weak Weak Operating income divided by interest expense Optimal: > 5x	-33.03x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-10.71x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$13.34M	$-23.66M	$-53.17M	$-87.29M	$-117.87M	$-152.60M	$-196.33M	$-226.86M	—	$-70.96M	—	—	—	—
Debt / EBITDA (x)	-5.76x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-3.31x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-3.01x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-3.71x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-2.34x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-2.35x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	—	—	$0.00	$0.08	$0.00	—	$0.00	$0.01	$0.00	—	$0.01	$0.00	—	—
Basic EPS, GAAP (USD)	$-2.15	$-2.11	$-2.28	$-1.85	$-2.80	$-5.03	$-2.84	$127.10	$-5.77	$-7.29	$-4.39	$-4.31	—	—
Free Cash Flow per Share (USD)	$-2.44	—	$-2.19	$-1.94	$-2.32	—	—	—	$-4.70	—	$-4.67	—	—	—
Book Value per Share (USD)	$-1.44	$0.55	$2.54	$4.74	$6.52	$9.23	$12.33	$15.15	$0.85	$0.92	$10.99	$-2.27	—	—
Tangible Book Value per Share (USD)	$-1.44	$0.55	$2.54	$4.74	$6.52	$9.23	$12.33	$15.15	$0.85	$0.92	$10.99	$-2.27	—	—
Basic Weighted Avg Shares (shares)	15.59M	—	15.48M	15.47M	15.47M	—	15.47M	14.62M	13.64M	—	11.79M	10.91M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$144.83M	$99.03M	$125.44M	$155.03M	$179.75M	$119.67M	$163.35M	$203.00M	—	$239.05M	—	—	—	—
LT Debt (USD)	$174.99M	$100.56M	$99.92M	$99.28M	$98.65M	$0.00	$0.00	$0.00	—	$206.97M	—	—	—	—
Total Equity (USD)	$-21.04M	$7.99M	$36.83M	$68.56M	$94.44M	$133.58M	$178.47M	$219.37M	$11.57M	$43.50M	$129.59M	$-24.81M	$15.13M	$58.06M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	—	$0.00	$0.00	$1.30M	$0.00	$100.00K	$0.00	$100.00K	$0.00	$1.63M	$119.00K	$30.00K	—	—
Depreciation Expense (USD)	$537.00K	$564.00K	$582.00K	$662.00K	$675.00K	$689.00K	$760.00K	$475.00K	$360.00K	$298.00K	$304.00K	$295.00K	—	—
Net Income, GAAP (USD)	$-33.44M	$-32.83M	$-43.31M	$-43.31M	$-43.31M	$-47.87M	$-78.71M	$-78.71M	$-78.71M	$-93.60M	$-48.92M	$-48.92M	—	—
Operating Cash Flow (USD)	$-38.03M	$-30.12M	$-33.82M	$-29.95M	$-35.90M	$-43.72M	—	—	$-63.05M	$-56.82M	$-54.24M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

Inhibrx Biosciences, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare INBX with peers